Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.
Standard
Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study. / Walcher, Thomas; Walcher, Daniel; Hetzel, Jürgen; Mielke, Catrin; Rau, Matthias; Rittig, Kilian; Balletshofer, Bernd; Schwedhelm, Edzard; Hombach, Vinzenz; Böger, Rainer; Koenig, Wolfgang; Marx, Nikolaus.
in: DIABETES VASC DIS RE, Jahrgang 7, Nr. 3, 3, 2010, S. 178-185.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.
AU - Walcher, Thomas
AU - Walcher, Daniel
AU - Hetzel, Jürgen
AU - Mielke, Catrin
AU - Rau, Matthias
AU - Rittig, Kilian
AU - Balletshofer, Bernd
AU - Schwedhelm, Edzard
AU - Hombach, Vinzenz
AU - Böger, Rainer
AU - Koenig, Wolfgang
AU - Marx, Nikolaus
PY - 2010
Y1 - 2010
N2 - Antidiabetic thiazolidinediones (TZDs) improve endothelial function in patients with or without type 2 diabetes. The present randomised, placebo-controlled, double-blind study examined the time course of a single dose of rosiglitazone on flow-mediated endothelium-dependent vasodilation (FMD), metabolic parameters, and its effect on inflammatory markers in non-diabetic men. Forty non-obese, healthy men with normal glucose tolerance were randomised to a single dose of rosiglitazone (8 mg) or placebo, and FMD was assessed at baseline as well as after 6 h and 24 h. Rosiglitazone did not significantly affect blood glucose and insulin levels or lipid parameters after 6 and 24 h compared with placebo. Treatment with rosiglitazone significantly increased FMD after 6 h from 4.3% (3.3; 4.9) to 7.6% (5.6; 9.2) (p
AB - Antidiabetic thiazolidinediones (TZDs) improve endothelial function in patients with or without type 2 diabetes. The present randomised, placebo-controlled, double-blind study examined the time course of a single dose of rosiglitazone on flow-mediated endothelium-dependent vasodilation (FMD), metabolic parameters, and its effect on inflammatory markers in non-diabetic men. Forty non-obese, healthy men with normal glucose tolerance were randomised to a single dose of rosiglitazone (8 mg) or placebo, and FMD was assessed at baseline as well as after 6 h and 24 h. Rosiglitazone did not significantly affect blood glucose and insulin levels or lipid parameters after 6 and 24 h compared with placebo. Treatment with rosiglitazone significantly increased FMD after 6 h from 4.3% (3.3; 4.9) to 7.6% (5.6; 9.2) (p
M3 - SCORING: Zeitschriftenaufsatz
VL - 7
SP - 178
EP - 185
JO - DIABETES VASC DIS RE
JF - DIABETES VASC DIS RE
SN - 1479-1641
IS - 3
M1 - 3
ER -